LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?

Eli Lilly hit a record high after CVS expanded coverage for its obesity drugs Foundayo and Zepbound, improving patient access and supporting prescription growth. The move strengthens Lilly’s competitive position versus Novo Nordisk (NVO) and signals broader payer acceptance of obesity treatments. The news is supportive for Lilly shares and modestly positive for the obesity-drug category.

Analysis

Eli Lilly hit a record high after CVS expanded coverage for its obesity drugs Foundayo and Zepbound, improving patient access and supporting prescription growth. The move strengthens Lilly’s competitive position versus Novo Nordisk (NVO) and signals broader payer acceptance of obesity treatments. The news is supportive for Lilly shares and modestly positive for the obesity-drug category.